and All EBM will be systematically searched for randomised controlled trials (RCTs) and systematic reviews of RCTs, comparing vitamin D supplementation with placebo, usual care or other pharmacological or non-pharmacological interventions. One reviewer will assess articles for eligibility according to prespecified selection criteria, after which 2 independent reviewers will perform data extraction and quality appraisal. Meta-analyses will be conducted where appropriate.
Methods and analysis: Medline, CINAHL, EMBASE
and All EBM will be systematically searched for randomised controlled trials (RCTs) and systematic reviews of RCTs, comparing vitamin D supplementation with placebo, usual care or other pharmacological or non-pharmacological interventions. One reviewer will assess articles for eligibility according to prespecified selection criteria, after which 2 independent reviewers will perform data extraction and quality appraisal. Meta-analyses will be conducted where appropriate.
Ethics and dissemination: Formal ethical approval
is not required as no primary data is collected. This systematic review will identify potential clinical implications of vitamin D deficiency and supplementation, and will be disseminated through a peer-reviewed publication and at conference meetings, to inform future research on the efficacy of vitamin D supplementation for inflammation and inflammatory diseases.
INTRODUCTION
Vitamin D has traditionally been known for its role in regulating calcium and phosphorus for the healthy mineralisation of bone. Recent evidence has broadened interest to the role of vitamin D in extraskeletal functions, including in inflammation and immunoregulation. 1 2 The functions of vitamin D in inflammation are of increasing interest, and vitamin D deficiency has been implicated in the pathophysiology of various inflammatory diseases including Crohn's disease and rheumatoid arthritis, as well as in conditions associated with chronic low-grade inflammation, such as obesity, insulin resistance, type 2 diabetes and cardiovascular disease. 3 The interaction between vitamin D and inflammation may have clinical implications, as vitamin D deficiency remains prevalent worldwide and is increasing as a result of sedentary indoor lifestyles and the use of sunscreen and protective clothing to reduce the risk of skin cancer. 4 At present, there is no universal consensus on optimal levels of vitamin D, but most experts agree that plasma 25-hydroxyvitamin D levels <50 nmol/L would be considered deficient. 5 It is therefore concerning that 20-60% of the UK and 10-40% of the US population have vitamin D levels <50 nmol/L. 6 Despite the sunny climate in Australia, vitamin D deficiency is prevalent in 50% of women and 31% of men. 7 Vitamin D can be obtained from dietary sources or supplements in the form of cholecalciferol or ergocalciferol, although it is primarily derived via conversion of 7-dehydrocholesterol in the skin consequent to exposure to ultraviolet B radiation. 8 However, recommendations to prevent skin cancer by reducing sun exposure have made it difficult to obtain adequate vitamin D Several studies have attempted to delineate the effects of vitamin D on inflammatory cells and processes. In vitro, vitamin D has been shown to promote monocyte differentiation to macrophages, preventing them from releasing inflammatory cytokines and reducing their ability to present antigens to lymphocytes by inhibiting cell surface expression of the class 2 major histocompatibility complex (MHC-II) molecule.
2 Vitamin D also suppresses the proliferation and stimulatory abilities of T cells and monocytes, and downregulates proinflammatory cytokines, including C reactive protein (CRP), tumour necrosis factor α (TNFα), interleukin (IL) 6, IL-1 and IL-8, while upregulating anti-inflammatory cytokines such as IL-10. 2 In vitro data has also shown associations between absence of the VDR and increased nuclear factor κB (NFκB) activity, a transcription factor with a key role in immunomodulation, and in the pathophysiology of several inflammatory diseases and chronic inflammatory states. 11 The reverse was also evident, where vitamin D was shown to prevent NFκB translocation and weaken its activity.
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In vivo studies using animal models have shown that supplementation with 1,25OHD prevented the development of inflammatory arthritis, type 1 diabetes and autoimmune encephalomyelitis and thyroiditis. [12] [13] [14] [15] Administration of 1,25OHD to non-obese, non-diabetic mice also modulated chemokine and cytokine expression and prevented diabetes. 16 Conversely, VDR knockout mice developed severe diarrhoea and rectal bleeding, suggesting that vitamin D deficiency may compromise the integrity of the intestinal mucosal barrier, thereby increasing susceptibility to mucosal damage and development of inflammatory bowel disease. 17 Human observational studies have frequently reported that higher vitamin D levels were associated with lower inflammatory markers including CRP, IL-6 and TNFα in healthy populations, [18] [19] [20] and in those with proinflammatory conditions, such as diabetes, arteriosclerosis and inflammatory polyarthritis. 3 Vitamin D has also been associated with adipocytokines, with studies showing inverse correlations between vitamin D and leptin, 21 22 and positive correlations between vitamin D and adiponectin. 22 23 This latter action of vitamin D is thought to occur partly via down-regulating IL-6 since IL-6 has been shown to inhibit adiponectin gene expression. 23 24 It is biologically plausible that sufficient vitamin D levels may be important in modulating inflammatory processes, and this seems to be supported by various experimental and observational studies. 1 2 However, observational studies are limited given their high risk of bias and inability to establish causation or directionality. Moreover, randomised controlled trials (RCTs) and systematic reviews of RCTs to date have focused on specific population groups, such as children, 25 26 or inflammatory conditions, such as obesity, inflammatory bowel disease and chronic obstructive pulmonary disease. [27] [28] [29] [30] Thus, there remains a gap in knowledge of the effects of vitamin D supplementation on inflammatory markers or states across the wider general population. This systematic review, therefore, aims to address this gap by identifying and comprehensively synthesising evidence evaluating the effect of vitamin D supplementation on inflammation in all population groups. 
SYSTEMATIC REVIEW QUESTION

METHODS/DESIGN
Rigorous international gold-standard methodology will be adopted in this review, 31 32 and will conform to the reporting standards of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA). This systematic review has been registered on PROSPERO under the identification code: CRD42016037104.
Eligibility criteria
Selection criteria using the PICO (Population, Intervention, Comparison, Outcomes) framework in table 1 established a priori will be used to determine eligibility of articles.
SEARCH STRATEGY
A systemic search will be developed using relevant search terms (see online supplementary file 1) in accordance with the selection criteria ( Bibliographies of relevant studies identified by the search strategy and relevant reviews/meta-analyses will also be searched for identification of additional studies. Corresponding authors of any included trials where required data are not presented will be contacted to provide deidentified data (aggregated effect measures) for the purpose of meta-analysis, if deemed appropriate. To identify unpublished studies we will also search the National Institute of Health Clinical Trials Register (https://clinicaltrials.gov/) and the Australian New Zealand Clinical Trials registries (https://www.anzctr. org.au).
Inclusion of studies
To determine the literature to be assessed further, one reviewer will scan the titles, abstract sections and keywords of every record retrieved by the search strategy using the selection criteria described in table 1, and in consultation with a second reviewer. Disagreement between reviewers about whether a study meets the inclusion criteria will be resolved by discussion. Where consensus is not reached, a third reviewer will be consulted to reach a decision. A pilot test of the selection criteria will be conducted on 3-5 articles in order to refine and clarify the criteria prior to screening. Full articles will be retrieved for further assessment if the information given suggests that the study meets the selection criteria. Where there is any doubt regarding eligibility from information provided in the title and abstract, the full article will be retrieved for clarification. Studies excluded based on full text will be tabulated with the reason/s for their exclusion.
Quality appraisal of the evidence Methodological quality, in terms of risk of bias, of the included studies will be assessed at the study level by two independent reviewers using criteria developed a priori, as outlined in the Monash Centre for Health Research and Implementation critical appraisal template. 33 Individual quality items will be investigated using a descriptive component approach that includes items such as conflict of interest of authors, presence of prespecified selection criteria, methods of randomisation and allocation of participants to study groups, blinding of participants, carers, investigators or outcome assessors, methods of outcome assessment and reporting, and statistical issues, such as powering and methods of data analysis (see online supplementary file 2). Any disagreement or uncertainty will be resolved by discussion among review authors to reach a consensus. Using this approach, each study will be allocated a risk of bias rating. 33 Data extraction Data will be extracted from all included studies by two independent reviewers using a specifically developed data extraction form in line with the selection criteria and outcomes of interest (table 1) . Both reviewers will ADMA, assymetric dimethylarginine; hsCRP, high sensitivity C reactive protein; ICAMs, intracelleular adhesion molecules; IFNγ, interferon γ; MCP-1, monocyte chemotactic protein 1; MIF, macrophage migration inhibitory factor; MMPs, matrix metalloproteinases; NFκB, nuclear factor κB; PAI-1, plasminogen activator inhibitor 1; RCT, randomised controlled trial; SAA, serum amyloid A; TGF-β1, tumour growth factor 1; TNFα, tumour necrosis factor α.
check all computed data entries for meta-analyses, if applicable. Extracted data will include mean values and SDs of the outcomes, and their CIs, point estimates and measures of variability, frequency counts for dichotomous variables, number of participants, intention-to-treat analysis, and validity results.
Outcomes may be reported as continuous measures of these inflammatory biomarkers, and in such cases, the mean or standardised mean difference along with their SDs and CIs will be used to measure the effects (see online supplementary file 2). Eligible outcomes may also be dichotomous and, as such, will include relative measures of inflammation risk (risk ratio or OR along with CIs), or absolute numbers of patients experiencing at least one episode of inflammation.
Grading the body of evidence
The quality of the evidence for the effects of vitamin D supplementation on inflammatory markers and diseases will be assessed as high, moderate, low or very low using the GRADE approach. 34 Quality of evidence will be graded by two independent reviewers based on risk of bias, imprecision, heterogeneity, indirectness and suspicion of publication bias. Quality will be reported at the study level, and where appropriate, at the outcome level, in line with PRISMA guidelines. Disagreements will be resolved by discussion, and where consensus cannot be reached, a third reviewer will be consulted. Interpretation of the grading scores is presented in table 2.
DATA ANALYSIS AND SYNTHESIS Planned analyses
Data will be presented in summary tables and in narrative form to describe the populations, interventions and outcomes of the included studies. Where data is available, or could be imputed or obtained from authors, between-group differences will be presented, and relative differences in outcomes will be assessed. Log transformation will be conducted where necessary. Aggregated effect measures will be used for meta-analyses where appropriate, when data are derived from clinically homogeneous groups (where participants, interventions and outcome measures are sufficiently similar), using a random effects model in Review Manager 5.3.5. Dichotomous outcomes will be presented as relative risks with 95% CIs, while continuous outcomes will be presented as weighted mean differences with 95% CIs. A p value of <0.05 will indicate statistical significance.
Statistical heterogeneity will be assessed using the I 2 test, where I 2 values over 50% indicate moderate to high heterogeneity. Descriptive analyses will be conducted for those studies which are deemed clinically heterogeneous, or present insufficient data for pooling.
Subgroup and sensitivity analyses
Subgroup analyses, or if applicable, metaregression analyses will be performed for factors presumed to cause variations in outcomes, and may include age, body mass index, dosage regimen, deficiency of participants at baseline, participant disease status and study duration. Sensitivity analysis will be conducted if deemed appropriate, and factors to be included will be determined during the review process. Heterogeneity I 2 >50% will be explored through sensitivity analysis using risk of bias. For meta-analyses of more than 10 studies, funnel plots will be used to determine small study effects and potential publication bias.
DISCUSSION
Although inflammatory processes are crucial for the human host defence against infectious agents and injury, prolonged systemic inflammation contributes to the pathophysiology of many chronic diseases. 1 Moreover, there is limited knowledge on the potential of naturally occurring nutrients, such as vitamin D, in improving these inflammatory states and conditions.
To the best of our knowledge, this will be the first comprehensive systematic review investigating the effectiveness of vitamin D supplementation in improving inflammation in all populations, as previous reviews have been limited to investigating specific inflammatory conditions or population groups. 26 28 30 In addition, this review will include trials investigating inflammation independently, and/or as a risk factor in the pathophysiology of cardiometabolic diseases such as type 2 diabetes, heart disease or chronic inflammatory conditions such as Crohn's disease and rheumatoid arthritis. There is also a lack of sound evidence to justify biological or sociological differences between population subgroups, hence, the additional benefit of including populations of all ages and backgrounds in this review. Our systematic review will use rigorous methodology, prespecified criteria and predetermined outcomes in order to comprehensively examine and synthesise the literature and assess the effects of vitamin D supplementation on inflammatory markers and diseases in a variety of populations.
Although outside of our control, this systematic review is limited by its reliance on published data, and thus, publication bias cannot be ruled out as there may be unpublished findings that are unaccounted for.
This systematic review will investigate the impact of vitamin D supplementation on inflammation, and identify knowledge gaps to inform future research in the field. If vitamin D supplementation improves inflammation on systematic review and meta-analyses, we will generate level 1 evidence of efficacy with important implications for clinical practice.
